How We Rank Tirzepatide Programs

What we score

Every program is scored on six dimensions with fixed weights: pricing transparency (25%), clinical oversight (25%), pharmacy disclosure (20%), billing fairness (15%), access breadth (10%) and responsiveness to our questions (5%).

Pricing transparency asks whether the price at 10 mg and 15 mg is discoverable before you hand over contact details, whether fees are itemised, and whether renewal pricing is stated. A program that only reveals price after capturing your details cannot score above average here regardless of how low the price turns out to be.

What we verify, and how often

Prices are checked against the program's own published pages and, where pricing is gated, against quotes supplied to us in writing. Every price on the site carries the date it was last checked. Where a figure is provider-reported rather than independently observed, the provider page says so.

We re-check the full price grid at least monthly and after any provider announcement. Changes are logged.

What we refuse to score

We do not score patient outcomes, because no program publishes verifiable outcome data and self-reported before-and-after material is not evidence. We do not score customer service from review-site averages alone, because review volumes differ by orders of magnitude between programs and small samples are noise.

We do not accept payment for placement, and we do not allow a program to review its page before publication.

How a program moves

Publishing dose-tier pricing, naming the compounding pharmacy, naming the prescribing entity, and stating refund terms are the four fastest ways for a program to improve its score. All four cost nothing and all four are within the program's control.

Corrections are published with a dated note. If we get something wrong, tell us at the corrections address and we will fix it and say that we did.

How We Rank Tirzepatide Programs: how this site is actually built

Every price table, ranking and comparison on this site is generated from a structured dataset rather than written by hand. That has one consequence worth stating plainly: rankings are computed, not chosen. We cannot quietly move a program up a table, because there is no table to edit — there is a dataset and a sort order, both published. The dataset is downloadable, and so is the formula for the disclosure score.

We currently track 44 routes to tirzepatide or semaglutide, priced at all six dose tiers, with entry pricing for compounded preparations starting at $133 per month. Every record carries the date it was last verified, because a price without a date is not a fact, it is a memory.

How We Rank Tirzepatide Programs: what we will not do

We will not publish a price we cannot interpret. A figure advertised without the dose it applies to or the period it covers is left blank rather than estimated, and the blank is deliberate. We will not invent review counts, ratings or testimonials. We will not describe a compounded preparation as equivalent to an FDA-approved product, because FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before marketing. And we will not accept payment for placement, for position, or for the removal of a criticism.

How We Rank Tirzepatide Programs: the disclosure score in full

The score measures what a program publishes before you pay — not the quality of its care, which we have no way to measure and will not pretend to. Its seven inputs and weights:

1. Price published at all six dose tiers — 25 points.
2. Price does not rise as the dose escalates — 20 points.
3. Dispensing pharmacy or prescriber identified by name — 15 points.
4. No separate recurring membership fee — 10 points.
5. Prepaid term and its rate published — 10 points.
6. State availability published — 10 points.
7. Delivery formats published — 10 points.

All seven are derivable from the published dataset, which means anyone can recompute the number and get the same answer. If you think the weighting is wrong, take the data and weight it differently; that is why it is published.

How We Rank Tirzepatide Programs: how we handle conflicting sources

Where two sources give different prices for the same program, we show both, name each source and its date, and state that neither has been independently verified. Choosing one silently would produce a cleaner table and a less honest one. Those conflicts appear as callouts on the affected program pages.

How We Rank Tirzepatide Programs: commercial relationships

Some outbound links are commercial and may earn a commission. Commissions do not influence rankings, scores or published prices. Table order is computed from the published dataset rather than assigned, so the ranking can be reproduced from the files on the data page. Where we have no outbound link for a program, the page says so and suggests searching for it directly rather than following an advertisement. See the advertising disclosure for the full statement.

How We Rank Tirzepatide Programs: corrections

Substantive errors — a wrong price, a misstated dose, an incorrect trial result, a ranking moved by bad data — are logged publicly with the date they were fixed. A site publishing prices in a fast-moving market that never records a correction is not being careful; it is not checking. Report anything you believe is wrong through contact with the page URL and, if you have one, a source.

How We Rank Tirzepatide Programs: what this site is not

It is not medical advice, it is not a pharmacy, and it does not sell medication. Tirzepatide is a prescription medicine, and only a licensed clinician who has reviewed your history can decide whether it is appropriate for you. Compounded preparations are not FDA-approved. If a program guarantees approval before a clinician has seen your record, that is the clearest warning sign available in this market, and no price justifies it.

How We Rank Tirzepatide Programs: why any of this is worth stating

Health-adjacent comparison sites are structurally conflicted. They are funded by commissions from the companies they rank, which creates an incentive to rank the highest-paying option first and to describe the arrangement vaguely. The defences against that are boring and checkable: publish the dataset, publish the formula, compute the ranking rather than choosing it, disclose the commercial relationships in the same typeface as everything else, and log corrections publicly with dates.

None of that proves good faith. It does make bad faith detectable, which is the most any publisher can honestly offer. If our ranking and our published dataset ever disagree, that is a bug or a lie, and either way you can find it without our help.

How We Rank Tirzepatide Programs: how to check us

Download providers.json and sort it yourself by twelve-month cost. The order should match our tables. Recompute the disclosure score from the criteria and weights on the data page; the numbers should match the badges. Follow a trial citation to its registration record and confirm the endpoint we quoted was the primary one. Any mismatch is a reportable error and goes in the corrections log with the date it was fixed.

How We Rank Tirzepatide Programs: the limits of what a website can do

We can tell you what a program publishes and what it costs at each dose. We cannot tell you whether its clinicians are good, whether its shipments arrive on time, or whether tirzepatide is appropriate for you. The first two we do not measure and will not guess at; the third belongs to a licensed clinician with your medical history in front of them. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing, and no amount of comparison shopping changes that distinction.

How We Rank Tirzepatide Programs: the numbers behind the site

We track 44 routes to tirzepatide or semaglutide, priced at all six dose tiers, with compounded entry pricing from $133 to $399 a month and a cheapest twelve-month total of about $2,388. Every figure carries a verification date. Anything older than a month should be re-checked before you act on it, including by us.